What is CardioFocus?
CardioFocus is at the forefront of developing advanced electrophysiology tools designed to treat atrial fibrillation, a common heart rhythm disorder. The company's core innovation lies in its pulsed field ablation technology, which offers a precise and efficient method for cardiac ablation procedures. Their product suite includes sophisticated catheters and generators engineered to enhance treatment outcomes for electrophysiologists. By providing integrated therapy platforms, CardioFocus aims to streamline clinical workflows and improve the quality of care for patients suffering from cardiac arrhythmias. The company's focus on cutting-edge medical devices positions it as a key player in the rapidly evolving field of cardiac electrophysiology.
How much funding has CardioFocus raised?
CardioFocus has raised a total of $235.3M across 16 funding rounds:
Multiple Rounds
$49.2M
Multiple Rounds
$36.3M
Private Equity
$8M
Private Equity
$20.2M
Debt
$21M
Unspecified
$55M
Debt
$1M
Private Equity (2011): $13.6M, investors not publicly disclosed
Unspecified (2011): $30.6M led by Oxford Bioscience Partners, Fletcher Spaght Ventures, H.I.G. Capital, KBL Healthcare Ventures, Manatuck Hill Partners, First Alliance & Capital Invest, The Aurora Funds, Inc., Accuitive Medical Ventures, and SV Life Sciences
Debt (2011): $5M supported by Silicon Valley Bank
Debt (2014): $2.4M featuring Fletcher Spaght Ventures, LP, Oxford Bioscience Partners, H.I.G. Capital, The Aurora Funds, Accuitive Medical Ventures, and SV Life Sciences
Debt (2014): $2.3M backed by Aurora Funds, Accuitive Medical Ventures, S.V. Life Sciences, Allied Minds, and KBL Healthcare Ventures
Private Equity (2014): $31.7M with participation from H.I.G.. BioVentures, Aurora Funds, Accuitive Medical Ventures, S.V. Life Sciences, Allied Minds, and KBL Healthcare Ventures
Private Equity (2016): $8M led by S.V. Life Sciences, Aurora Funds, Accuitive Medical Ventures, H.I.G. BioVentures, Allied Minds, and KBL Healthcare Ventures
Private Equity (2017): $20.2M, investors not publicly disclosed
Debt (2018): $21M featuring GPB Capital
Unspecified (2019): $55M backed by Kennedy Lewis Investment Management
Debt (2020): $1M with participation from PPP
Key Investors in CardioFocus
S.V. Life Sciences
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, partnering with founders and management to provide capital, sector expertise and active support from early growth through scale and value creation.
Aurora Funds
The Aurora Funds is a venture capital firm that provides capital, connections and strategic guidance to entrepreneurs with early-stage healthcare and information technology companies. Founded in 1994, Aurora manages over $234 million in five venture funds. The firm's three investment professionals have over 45 years of combined venture capital investing and operational experience.
Accuitive Medical Ventures
Accuitive Medical Ventures is a venture capital firm with committed capital of $230 million. We have offices in Atlanta, GA and Amelia Island, FL. We are a market driven firm looking for revolutionary medical device technology investment opportunities. Accuitive specializes in two distinct types of investments: Venture financing for companies with outstanding technology and teams Venture financing and management of technologies being developed within The Innovation Factory Accuitive Medical Ventures has a strong relationship with The Innovation Factory (TIF), the successful medical technology serial operating team. TIF has started thirteen companies since 1999 and is based in Atlanta, GA. In conjunction with TIF, Accuitive Medical Ventures has the resources and experience to create long-term value for all medical technology stakeholders. Accuitive has established relationships with some of the industry's leading institutions to offer emerging companies and investors the opportunity to build unique new businesses and long-term shareholder value. Accuitive's connections to some of the industry's leading practitioners, thought leaders and venture capital firms enable us to add substantial value as investors and board members.
What's next for CardioFocus?
With the recent infusion of major strategic capital, CardioFocus is poised for accelerated growth and market expansion. The company is expected to leverage this investment to further develop its pulsed field ablation technology, scale its manufacturing capabilities, and broaden its commercial reach. This funding will likely support clinical trials, regulatory approvals, and the expansion of its sales and marketing efforts globally. CardioFocus's strategic direction points towards solidifying its position as a leader in electrophysiology solutions, driving innovation in the treatment of atrial fibrillation and other cardiac conditions.
See full CardioFocus company page
